Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of cancer called a gastroenteropancreatic neuroendocrine tumour (GEP-NET), recorded in medical records at some point between 1 January 2018 and 31 December 2025.
- People who started a first course of treatment for GEP-NET — such as certain hormone-like drugs, targeted medicines, a type of radiation therapy, or chemotherapy — on or after the date their diagnosis was first recorded.
- People who were 18 years of age or older when they started that first treatment.
- People whose health insurance or medical records show continuous coverage for at least 12 months before their treatment start date, with medical or pharmacy claims spread across that period (confirm with trial site).
- People whose health records show at least one month of data after their treatment start date, including records from the pharmacy or prescribing doctor who provided the GEP-NET treatment (confirm with trial site).
Who may not be able to join:
- People whose records show signs of GEP-NET before the date their diagnosis was first officially recorded within the study period.
- People whose records show they received GEP-NET treatment before the date their first treatment was officially recorded within the study period.
- People whose age or sex is missing or recorded incorrectly in their medical records.
- People who had another separate primary cancer diagnosed in the 12 months before their GEP-NET treatment start date.
- People whose records contain an invalid death date — for example, where the recorded date of death is listed as the same day as or earlier than their treatment start date.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: +41613241111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Lines of Therapy (LOTs); Number and Percentage of Patients by Treatment Regimen per LOT; Number and Percentage of Patients by Type of Therapy in Each LOT; Number and Percentage of Patients who Discontinue all Medications Within the 1L Treatment Regimen; Number of Cycles of Medications Within the Treatment Regimen Before Discontinuation; Time to 1L Treatment Discontinuation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.